Contraceptive applications of estrogen

Journal of Midwifery and Women's Health

Volumn 47, Issue 3, 2002, Pages 139-156

  Likis, Frances E ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; APRI; AVIANE; CYCLESSA; DEMULEN 1 35; DEMULEN 1 50; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL CIPIONATE; ESTROGEN; ESTROSTEP; ETHINYL ESTRADIOL NORGESTREL COMBINATION; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETYNODIOL DIACETATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; ETYNODIOL DIACETATE; GESTAGEN; INJECTABLE CONTRACEPTIVE AGENT; JENEST 28; LEVLITE; LEVONORGESTREL; LEVORA; LOESTRIN 1 20; LOW OGESTREL; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; MESTRANOL; NECON 1 35; NELOVA 1 35; NORETHIN 1 35; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; NORGESTREL; NORINYL 1 35; NORLESTRIN 1 50; OGESTREL; ORAL CONTRACEPTIVE AGENT; ORTHO NOVUM 1 35; ORTHO TRI CYCLE; OVCON 50; PLACEBO; POSTCOITUS CONTRACEPTIVE AGENT; TRANQUILIZER; TRIVORA; UNINDEXED DRUG; ZOVIA 1 35; ZOVIA 1 50;

ADULT; AMENORRHEA; APPETITE DISORDER; ARTICLE; BLEEDING; BREAST DISEASE; CATARACT; CEREBROVASCULAR ACCIDENT; CHLOASMA; CONTRACEPTION; CYSTITIS; DEPRESSION; DRUG COMBINATION; DRUG CONTRAINDICATION; DRUG FORMULATION; DRUG MECHANISM; EDEMA; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; FEMALE INFERTILITY; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HUMAN; HYPERTENSION; INJECTION; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; LACTATION DISORDER; MENSTRUATION DISORDER; METHODOLOGY; MIGRAINE; NAUSEA; OBSTRUCTIVE JAUNDICE; RASH; SIDE EFFECT; THROMBOEMBOLISM; THROMBOPHLEBITIS; TRANSDERMAL PATCH; UTERINE CERVIX EROSION; UTERUS DISEASE; VAGINA CANDIDIASIS; VAGINA RING; VEIN THROMBOSIS; WEIGHT GAIN; WEIGHT REDUCTION; REVIEW;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRAVAGINAL; ADULT; CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, POSTCOITAL; DRUG COMBINATIONS; ESTROGENS; ETHINYL ESTRADIOL-NORGESTREL COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MEDROXYPROGESTERONE;

EID: 0035984011     PISSN: 15269523     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-9523(02)00234-9     Document Type: Article

References (64)

1. The pill: A biography of the drug that changed the world
2. Estrogen: Physiology, pharmacology, and formulations for replacement therapy
3. Trends in contraceptive use in the United States: 1982-1995
4. Improving access to quality care in family planning
5. Ovarian activity in women taking an oral contraceptive containing 20 μg ethinyl estradiol and 150 μg desogestrel: Effects of low estrogen doses during the hormone-free interval
6. Compliance, counseling and satisfaction with oral contraceptives: A prospective evaluation
7. How effective are contraceptives? The determination and measurement of pregnancy rates
8. Use and misuse of oral contraceptives: Risk indicators for poor pill taking and discontinuation
9. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices
10. The emerging use of the 20-μg oral contraceptive
11. Health benefits of oral contraceptives
12. Report of the Council of Scientific Affairs: Unlabeled indications of Food and Drug Administration-approved drugs
13. Oral contraceptive use in perimenopause
14. Menstruation: Choosing whether... and when
15. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms
16. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use
17. Oral contraceptive side effects: Where's the beef?
18. Putting risk in perspective: An evidence-based approach to selected risks associated with the use of oral contraception
19. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies
20. Breast cancer risk: Perception versus reality
21. Drospirenone: Pharmacology and pharmacokinetics of a unique progestogen
22. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen
23. Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence
24. Risk of drug interactions with St. John's Wort
25. Drug interactions between oral contraceptives and antibiotics
26. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol
27. Injectable contraception: New and existing options
28. Self-administration with Uniject® of the once-a-month injectable contraceptive Cyclofem®
29. Return of fertility after discontinuation of the once-a-month injectable contraceptive Cyclofem®
30. New option in hormonal contraception: Monthly combination contraceptive injection
31. Patient acceptability and satisfaction with Lunelle™ monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension)
32. Comparative safety, efficacy, and cycle control of Lunelle™ monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum® 7/7/7 oral (norethindrone/ethinyl estradiol triphasic)
33. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition
34. Hormonal contraception: A focus on the transdermal delivery system
35. Efficacy and safety of a transdermal contraceptive system
36. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: A randomized controlled trial
37. Emergency contraceptive pills: A simple proposal to reduce unintended pregnancies
38. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception
39. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception
40. The Yuzpe regimen of emergency contraception: How long after the morning after?
41. Effectiveness of emergency contraceptive pills between 72 and 120 hours after unprotected sexual intercourse
42. Prescription drug products; certain combined oral contraceptives for use as postcoital emergency contraception
43. The status of dedicated products
44. CRLP petitions FDA to change emergency contraception from prescription to over the counter: Emergency contraception safer than aspirin
45. Emergency contraception over-the-counter: The medical and legal imperatives
46. Position statement: Emergency contraception: Expanding education and access
47. Increasing access to emergency contraception through community pharmacies: Lessons from Washington state
48. Mechanisms of action of hormonal preparations used for emergency contraception: A review of the literature
49. Statistical evidence about the mechanism of action of emergency contraception
50. Emergency contraception: A guide to the provision of services
51. Meclizine for the prevention of nausea associated with use of emergency contraceptive pills: A randomized trial
52. The risk of venous thromboembolism in users of postcoital contraceptive pills